Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Follow-Up Questions
Fortress Biotech Inc 的 CEO 是谁？
Dr. Adm. Lindsay Rosenwald 是 Fortress Biotech Inc 的 Executive Chairman of the Board，自 2009 加入公司。
FBIOP 股票的价格表现如何？
FBIOP 的当前价格为 $9.08，在上个交易日 increased 了 0.77%。
Fortress Biotech Inc 的主要业务主题或行业是什么？
Fortress Biotech Inc 属于 Biotechnology 行业，该板块是 Health Care
